Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDEAVOR: ETX101 in Dravet Syndrome
NCT05419492Phase 2Recruiting
- Sponsor
- Encoded Therapeutics
- Start
- May 2024
- Primary completion
- Jun 2028
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of etx101 in Dravet syndrome (2 arms), sponsored by Encoded Therapeutics. Primary endpoint: Percent change in monthly countable seizure frequency. Started May 2024; status: recruiting.
02
Drugs
etx101
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on NCT05419492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05419492.